Article
Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction.
Oncogene - 1 Apr 2022
Landras Alexandra, Reger de Moura Coralie, Villoutreix Bruno O, Battistella Maxime, Sadoux Aurélie, Dumaz Nicolas, Menashi Suzanne, Fernández-Recio Juan, Lebbé Céleste, Mourah Samia
Abstract excerpt
More than 70% of human NRASmut melanomas are resistant to MEK inhibitors highlighting the crucial need for efficient therapeutic strategies for these tumors. CD147, a membrane receptor, is overexpressed in most cancers including melanoma and is associated with poor prognosis. We show here that CD147i, a specific inhibitor of CD147/VEGFR-2 interaction represents a potential therapeutic strategy for NRASmut...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.